enoximone sulfoxide has been researched along with enoximone in 5 studies
| Studies (enoximone sulfoxide) | Trials (enoximone sulfoxide) | Recent Studies (post-2010) (enoximone sulfoxide) | Studies (enoximone) | Trials (enoximone) | Recent Studies (post-2010) (enoximone) |
|---|---|---|---|---|---|
| 5 | 1 | 0 | 516 | 146 | 36 |
| Protein | Taxonomy | enoximone sulfoxide (IC50) | enoximone (IC50) |
|---|---|---|---|
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | 3.95 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | 3.95 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | 3.95 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 3.95 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 3.8 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 3.8 | |
| Endothelin-1 receptor | Sus scrofa (pig) | 2.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lissmann, H; Mitrovic, V; Neuzner, J; Pitschner, HF; Schlepper, M | 1 |
| Kates, RE; Lebsack, C; Mead, RH; Ruder, MA; Smith, N; Winkle, RA | 1 |
| Cooper, JD; Turnell, DC | 1 |
| Boxenbaum, H; Hook, RH; Okerholm, RA; Thompson, GA | 1 |
| Chan, KY; Lang, JF; Ohlweiler, DF; Okerholm, RA | 1 |
1 trial(s) available for enoximone sulfoxide and enoximone
| Article | Year |
|---|---|
Disposition kinetics of orally administered enoximone in patients with moderate to severe heart failure.
Topics: Administration, Oral; Adult; Aged; Cardiotonic Agents; Enoximone; Female; Half-Life; Heart Failure; Humans; Imidazoles; Male; Metabolic Clearance Rate; Middle Aged; Time Factors | 1991 |
4 other study(ies) available for enoximone sulfoxide and enoximone
| Article | Year |
|---|---|
[Continuous enoximone infusion in patients with severe heart failure in dilated cardiomyopathy, hemodynamic, neurohumoral, chemical laboratory and clinical results].
Topics: Aldosterone; Atrial Natriuretic Factor; Cardiomyopathy, Dilated; Cardiotonic Agents; Enoximone; Epinephrine; Heart Failure; Hemodynamics; Humans; Imidazoles; Infusions, Intravenous; Neurotransmitter Agents; Norepinephrine; Renin | 1991 |
Automatic preparation of human serum samples for analysis of the drug enoximone and its sulphoxide metabolite using high-performance liquid chromatography.
Topics: Autoanalysis; Cardiotonic Agents; Chromatography, High Pressure Liquid; Enoximone; Humans; Imidazoles; Indicators and Reagents; Spectrophotometry, Ultraviolet | 1986 |
Human serum and plasma protein binding of enoximone and its sulfoxide metabolite.
Topics: Animals; Blood Proteins; Cardiotonic Agents; Enoximone; Fatty Acids; Globulins; Hydrogen-Ion Concentration; Imidazoles; Male; Orosomucoid; Protein Binding; Rats; Rats, Inbred Strains; Temperature; Ultrafiltration | 1988 |
Simultaneous analysis of a new cardiotonic agent, MDL 17,043, and its major sulfoxide metabolite in plasma by high-performance liquid chromatography.
Topics: Cardiotonic Agents; Chromatography, High Pressure Liquid; Drug Stability; Enoximone; Humans; Imidazoles; Mass Spectrometry; Oxidation-Reduction; Time Factors | 1984 |